secondary myelodysplastic syndromes

Search with Google Search with Bing
Information
Disease name
secondary myelodysplastic syndromes
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT02122081 Completed Phase 1 Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies July 27, 2015 September 6, 2022
NCT00008177 Completed Phase 1 Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes July 27, 1999 December 15, 2010
NCT00015990 Completed Phase 2 Thalidomide in Treating Patients With Myelodysplastic Syndrome April 2001
NCT00025415 Completed Phase 1 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction August 2001
NCT00045396 Completed Phase 2 A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) June 2002
NCT00049504 Completed Phase 2 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer January 2002 February 2014
NCT01305200 Completed Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant March 2011 June 30, 2015
NCT01384513 Completed Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies August 4, 2011 November 16, 2022
NCT01427881 Completed Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies September 2011 July 2015
NCT01529827 Completed Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies February 28, 2012 August 29, 2019
NCT01567059 Completed Phase 2 Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome May 2012 June 2013
NCT01588015 Completed Phase 1 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant October 29, 2012 February 2, 2024
NCT01839916 Completed Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies April 4, 2013 August 2018
NCT02019069 Completed Phase 2 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome February 3, 2014 December 18, 2017
NCT00002798 Completed Phase 3 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome August 1996
NCT00084916 Completed Phase 2 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase April 2004
NCT00087204 Completed Phase 1 Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia May 2004
NCT00095797 Completed Phase 1 XK469R in Treating Patients With Refractory Hematologic Cancer October 2004
NCT00096122 Completed Phase 1/Phase 2 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia September 2004 February 2010
NCT00098423 Completed Phase 1 Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes November 2004
NCT00098826 Completed Phase 1 SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes December 2004
NCT00104962 Completed Phase 1 Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes March 2005 June 2009
NCT00112593 Completed N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer November 1999
NCT00118287 Completed Phase 1/Phase 2 Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes April 2005
NCT00118352 Completed Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer March 2005 May 26, 2015
NCT00309907 Completed Phase 2 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant April 2006 September 2011
NCT00322101 Completed Phase 3 Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia January 2006 October 2014
NCT00331513 Completed Phase 1 Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes March 2006
NCT00343798 Completed Phase 1 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies April 2006
NCT00357162 Completed Phase 2 Belinostat in Treating Patients With Myelodysplastic Syndromes May 2006 December 2010
NCT00357305 Completed Phase 1 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders May 2006
NCT00369317 Completed Phase 3 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes March 2007 December 31, 2021
NCT00408681 Completed N/A Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant June 2006 May 1, 2015
NCT00445744 Completed N/A Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome December 2006 June 2013
NCT00450450 Completed Phase 3 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases December 31, 2007 March 31, 2022
NCT00451048 Completed Phase 2 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia February 2007 October 2012
NCT00459212 Completed Phase 1 GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia March 2007
NCT00462605 Completed Phase 2 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia April 2007 March 2011
NCT00475150 Completed Phase 2 Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome May 2008 March 2012
NCT00489203 Completed Phase 2 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer April 2007
NCT00795769 Completed Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant August 8, 2008 June 10, 2009
NCT00799461 Completed Phase 3 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications August 2008
NCT00856388 Completed N/A Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders January 14, 2009 March 13, 2019
NCT00860574 Completed Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia February 2009
NCT01041443 Completed Phase 1 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes December 2009 October 2013
NCT01083706 Completed Phase 2 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant April 2010
NCT01093586 Completed Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies September 2007 December 2015
NCT01146210 Completed Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia May 2009 May 2016
NCT01175785 Completed Phase 2 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies August 2010 August 2014
NCT01177371 Completed Phase 2 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma March 1988 February 2010
NCT01199562 Completed Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant December 2010 December 2013
NCT01233921 Completed N/A Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer September 2010
NCT00509249 Terminated Phase 2 Aflibercept in Treating Patients With Myelodysplastic Syndromes September 2007 December 2010
NCT01044745 Terminated Phase 2 Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer December 10, 2009 October 10, 2017
NCT01076270 Terminated N/A Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies June 2010 February 2011
NCT00119366 Terminated Phase 2 Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome May 2003 May 8, 2019
NCT00301769 Terminated Phase 1 SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia December 2005
NCT01159067 Terminated Phase 2 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload July 2010 August 9, 2011
NCT00049582 Terminated Phase 1 Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia September 2002
NCT01652014 Withdrawn Phase 2 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies January 2014 January 2017
NCT01558778 Withdrawn N/A Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant May 2012